Takeda
NICE rejects Takeda cancer drug over price concerns
July 12, 2010Sales and Marketing Cancer, Mepact, NICE, Takeda, bone cancer
UK cost-effectiveness watchdog NICE has rejected Takeda’s orphan bone cancer drug Mepact due to concerns over price. In its draft …
Frank Morich and Haruhiko Hirate join Takeda
June 30, 2010Sales and Marketing Takeda, appointment, sales and marketing
Takeda has made new two appointments, looking outside the company to fill a brace of executive-level positions. Dr Frank Morich …
Takeda appoints Kiyohiko Tamura
May 25, 2010Sales and Marketing Takeda, appointment, sales and marketing
Japanese pharma company Takeda has appointed Kiyohiko Tamura general manager of its newly established Office of the President & CEO. …
Takeda plans cuts, eyes mergers
May 17, 2010Research and Development, Sales and Marketing Takeda, job cuts
Takeda is planning to cut its workforce by 10% through a series of cuts that will predominantly be made to …
Takeda delays diabetes drug in Europe
June 4, 2009Research and Development, Sales and Marketing Takeda, diabetes
Takeda is to delay seeking European approval of its key drug candidate alogliptin, and instead take another two years to …
Takeda to market new bone cancer drug
May 20, 2009Research and Development, Sales and Marketing MA, Takeda
Takeda has gained the rights to the first treatment for a new malignant bone cancer affecting children and young adults. …
Takeda chooses US base for its global development headquarters
April 2, 2009Research and Development Takeda
Takeda Pharmaceutical Company is shifting its global development HQ from Japan to the US. The move will see that function …
NHS is behind us, says rep-free Takeda
March 1, 2005Sales and Marketing Davis, Takeda, sales and marketing
Takeda UK says new market research shows healthcare professionals and NHS managers are in favour of its revolutionary move away …
Takeda to launch ‘radically different’ approach to NHS
July 2, 2004NHS, Takeda, salesforce
Takeda UK has unveiled plans for what it calls a ‘radically different’ structure to its sales operations designed to liberate …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
